Corporatism and Big Pharma
The pharmaceutical industry has leveraged public policy to its benefit, prohibiting the federal government from discounts on drug prices through bulk purchases while using the tax code to develop Patient Assistance Foundations to claim charitable contributions as well as justifying moving income overseas to reduce tax liability. Consumers and taxpayers are left covering the costs of Big Pharma's corporatism. Regulatory reforms are proposed to make drug companies more socially responsible.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Publication date: 2016-04-01
More about this publication?
- Ethical Human Psychology and Psychiatry seeks to raise the level of scientific knowledge and ethical discourse, while empowering professionals who are devoted to principled human sciences and services unsullied by professional and economic interests.
- Information for Authors
- Membership Information
- Information for Advertisers
- Free Sample Issue
- Subscribe to this Journal
- Ingenta Connect is not responsible for the content or availability of external websites